贝前列腺素钠联合西洛他唑治疗下肢动脉粥样硬化性疾病的临床分析

Efficacy of beraprost sodium combined with cilostazol in the treatment of lower extremity atherosclerotic disease

目的探讨贝前列腺素钠联合西洛他唑治疗下肢动脉粥样硬化性疾病的临床效果。方法选取2013年11月至2015年10月就诊于本院的下肢动脉粥样硬化性疾病患者78例为研究对象,按随机数表法将其分为联合治疗组(贝前列腺素钠与西洛他唑联合治疗,39例)和单药治疗组(西洛他唑单药治疗,39例),两组患者均治疗4周。分别于治疗前及治疗后4周进行患者主观症状评分、踝肱指数(ABI)测量和6分钟步行试验(6-MWT)评定。结果治疗后4周,两组患者主观症状评分均低于治疗前(P<0.05),且联合治疗组患者主观症状评分低于单药治疗组(P<0.05);两组患者ABI和6-MWT评分均高于治疗前(P<0.05),但组间比较均无显著差异(P>0.05)。结论贝前列腺素钠联合西洛他唑治疗下肢动脉粥样硬化性疾病,可改善患者的主观症状,安全性良好。

Objective To evaluate the therapeutic effects of beraprost sodium combined with cilostazol in the treatment of lower extremity atherosclerotic disease（LEAD）. Method Collected 78 patients with LEAD which in our hospital as research objects from November 2013 to October 2015. They were randomly assigned into combined treatment group（beraprost sodium combined with cilostazol, 39 cases） and monotherapy group（cilostazol monotherapy, 39 cases）. Both groups were treated for two weeks. Before treatment and 4 weeks after treatment, the subjective symptoms, ankle or brachial index（ABI） and 6-minute walk test（6-MWT） were assessed betwwen the two groups. Result Subjective symptom scores were decreased at 4 weeks after treatment compared with before treatment（P〈0.05）, subjective symptom scores at 4 weeks after treatment were significantly lower in combined treatment group than monotherapy group（P〈0.05）. The ABI and 6-MWT scores 4 weeks after treatment were higher than before treatment（P〈0.05）. There were no significant differences between the two groups（P〉0.05）. Conclusion Beraprost sodium combined with cilostazol can improve the subjective symptoms of LEAD patients with safety.